PD Dr. med. Urban Novak
PD Dr. med. Urban Novak
Medical Oncology, Inselspital, Bern University Hospital
Verified email at insel.ch
Cited by
Cited by
Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53
TJ Grob, U Novak, C Maisse, D Barcaroli, AU Lüthi, F Pirnia, B Hügli, ...
Cell Death & Differentiation 8 (12), 1213-1223, 2001
The NF-κB negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas
U Novak, A Rinaldi, I Kwee, SV Nandula, P Rancoita, M Compagno, ...
Blood 113 (20), 4918-4921, 2009
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome
A Rinaldi, M Mian, E Chigrinova, L Arcaini, G Bhagat, U Novak, ...
Blood 117 (5), 1595-1604, 2011
BCL6 suppression of BCL2 via Miz1 and its disruption in diffuse large B cell lymphoma
M Saito, U Novak, E Piovan, K Basso, P Sumazin, C Schneider, M Crespo, ...
Proceedings of the National Academy of Sciences 106 (27), 11294-11299, 2009
HIV and human herpesvirus 8 co‐infection across the globe: systematic review and meta‐analysis
E Rohner, N Wyss, Z Heg, Z Faralli, SM Mbulaiteye, U Novak, M Zwahlen, ...
International journal of cancer 138 (1), 45-54, 2016
Oxaliplatin‐induced immune pancytopenia
BM Taleghani, S Fontana, O Meyer, N Ahrens, U Novak, MM Borner, ...
Transfusion 45 (5), 704-708, 2005
A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL)
U Novak, E Oppliger Leibundgut, J Hager, D Mühlematter, M Jotterand, ...
Blood, The Journal of the American Society of Hematology 100 (5), 1787-1794, 2002
Disparate expression of the PTEN gene: a novel finding in B‐cell chronic lymphocytic leukaemia (B‐CLL)
N Leupin, B Cenni, U Novak, B Hügli, HU Graber, A Tobler, MF Fey
British journal of haematology 121 (1), 97-100, 2003
HHV-8 seroprevalence: a global view
E Rohner, N Wyss, S Trelle, SM Mbulaiteye, M Egger, U Novak, ...
Systematic reviews 3 (1), 1-7, 2014
Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia
U Novak, TJ Grob, G Baskaynak, UR Peters, S Aebi, D Zwahlen, ...
Annals of oncology 12 (7), 981-986, 2001
Diagnosis of Burkitt lymphoma in due time: a practical approach
SB Cogliatti, U Novak, S Henz, U Schmid, P Möller, TFE Barth
British journal of haematology 134 (3), 294-301, 2006
Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial
A Davies, TE Cummin, S Barrans, T Maishman, C Mamot, U Novak, ...
The lancet oncology 20 (5), 649-662, 2019
Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use
U Bacher, E Shumilov, J Flach, N Porret, R Joncourt, G Wiedemann, ...
Blood cancer journal 8 (11), 1-10, 2018
CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas
MT Mélanie Juilland, Montserrat Gonzalez, Tabea Erdmann, Yara Banz, Zala ...
Blood 127, 1780-9, 2016
P73 status in B-cell chronic lymphocytic leukaemia
N Leupin, A Lüthi, U Novak, TJ Grob, B Hügli, H Graber, MF Fey, A Tobler
Leukemia & lymphoma 45 (6), 1205-1207, 2004
Prognostic factors for advanced‐stage human immunodeficiency virus‐associated classical Hodgkin lymphoma treated with doxorubicin, bleomycin, vinblastine, and dacarbazine plus …
JJ Castillo, M Bower, J Brühlmann, U Novak, H Furrer, PY Tanaka, ...
Cancer 121 (3), 423-431, 2015
Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
E Zucca, S Rondeau, A Vanazzi, B Østenstad, UJM Mey, D Rauch, ...
blood 134 (4), 353-362, 2019
The HIV protease inhibitor nelfinavir in combination with bortezomib and dexamethasone (NVd) has excellent activity in patients with advanced, proteasome inhibitor-refractory …
C Driessen, R Müller, U Novak, N Cantoni, D Betticher, N Mach, M Gregor, ...
Blood, The Journal of the American Society of Hematology 128 (22), 487-487, 2016
BeEAM conditioning with bendamustine-replacing BCNU before autologous transplantation is safe and effective in lymphoma patients
S Gilli, U Novak, BM Taleghani, GM Baerlocher, K Leibundgut, Y Banz, ...
Annals of hematology 96 (3), 421-429, 2017
Genomic analysis of Non‐Splenic Marginal Zone Lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from Memory B‐cells
U Novak, K Basso, L Pasqualucci, R Dalla‐Favera, G Bhagat
British journal of haematology 155 (3), 362-365, 2011
The system can't perform the operation now. Try again later.
Articles 1–20